TC 6987 (Targacept) success in Phase II Asthma study

A Phase II asthma study of TC 6987 from Targacept was a double blind, placebo controlled, parallel group trial conducted at 23 sites in the United States. The study enrolled 93 adult patients with persistent mild to moderate Asthma that were being treated with inhaled corticosteroids, and 90 patients completed the study. The study included a number of different efficacy measures, with change in forced expiratory volume (FEV1) from baseline to pre-dosing and two-hours post-dosing on the last day of the dosing period designated as the co-primary outcome measures. Adjunct TC-6987 outperformed adjunct placebo in the study from baseline to pre-dosing on day 28 (one-sided p = 0.09) and from baseline to two hours post dosing on day 28 (one-sided p = 0.07). FEV1 is the most frequently used index for assessing airway obstruction. The study also included assessments of safety, tolerability and pharmacokinetics of TC-6987.